Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation

Pharmacogenetics and Genomics

Volumn 24, Issue 4, 2014, Pages 211-219

  Senapati, Sabyasachi ^a   Singh, Shalini ^a   Das, Mitashree ^a,b   Kumar, Ashok ^c,f   Gupta, Rajiva ^c,g   Kumar, Uma ^c   Jain, Sanjay ^a,d,e   Juyal, Ramesh C ^b   Thelma, B K ^a  

^a UNIVERSITY OF DELHI   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^e SANTA FE INSTITUTE   (Mexico)

^f FORTIS HOSPITAL   (India)

^g Fortis Hospital ^*  (India)

Author keywords

genome wide analysis; methotrexate; rheumatoid arthritis; TYMS ENOSF1

Indexed keywords

METHOTREXATE; NUCLEOTIDE; PURINE; ANTIRHEUMATIC AGENT; DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; PEPTIDE SYNTHASE; THYMIDYLATE SYNTHASE;

ADULT; ARTICLE; BIOINFORMATICS; COHORT ANALYSIS; DAS28; DHFR GENE; ENOSF1 GENE; FEMALE; FPGS GENE; GENE; GENE CONTROL; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE METABOLISM; OVERLAPPING GENE; PHARMACOGENOMICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPORT VECTOR MACHINE; TREATMENT RESPONSE; TYMS GENE; ARTHRITIS, RHEUMATOID; GENETICS; MIDDLE AGED;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC LOCI; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIA; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 84896394396     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000036     Document Type: Article

References (53)

1. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, et al. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol 2006; 70:1832-1839.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-1593.
3. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542-2550.
4. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:249-255.
5. Baggott JE, Morgan SL, Ha TS, Alarcon GS, Koopman WJ, Krumdieck CL. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993; 11 (Suppl 8):S101-S105.
6. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951-1960.
7. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-2682.
8. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54:3095-3103.
9. Jekic B, Lukovic L, Bunjevacki V, Milic V, Novakovic I, Damnjanovic T, et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol 2013; 69:377-383.
10. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) 2009; 48:613-617.
11. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008; 18:1041-1049.
12. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Singh P, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 2009; 19:823-828.
13. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 2013; 3:227-234.
14. Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 2009; 34:355-361.
15. Milic V, Jekic B, Lukovic L, Bunjevacki V, Milasin J, Novakovic I, et al. Association of dihydrofolate reductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012; 30:1 78-183.
16. Smith CA, Arnett FC Jr. Diagnosing rheumatoid arthritis: current criteria. Am Fam Physician 1991; 44:863-870.
17. Indian Genome Variation Consortium. Genetic landscape of the people of India: a canvas for disease gene exploration. J Genet 2008; 87:3-20.
18. Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, Chakraborty M, et al. Ethnic India: a genomic view, with special reference to peopling and structure. Genome Res 2003; 13:2277-2290.
19. Reich D, Thangaraj K, Patterson N, Price AL, Singh L Reconstructing Indian population history. Nature 2009; 461:489-494.
20. Negi S, Juyal G, Senapati S, Prasad P, Gupta A, Singh S, et al. A genome-wide association study reveals ARL15, a novel non-HLA susceptibility gene for rheumatoid arthritis in north Indians. Arthritis Rheum 2013; 65:3026-3035.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
22. Yu K, Wang Z, Li Q, Wacholder S, Hunter DJ, Hoover RN, et al. Population substructure and control selection in genome-wide association studies. PLoS One 2008; 3:e2551.
23. Boser BE, Guyon I, Vapnik VA. Training algorithm for optimal margin classifiers. Proceedings of the Fifth Annual Workshop on Computational Learning Theory. Pittsburgh, PA: ACM Press; 1992.
24. Cortes C, Vapnik V Support vector networks. Machine Learn 1995; 20:273-297.
25. Waddell M, Page D, Zhan F, Barlogie B, Shaughnessy J Jr. Predicting cancer susceptibility from single-nucleotide polymorphism data: a case study in multiple myeloma. BIOKDD'05: Proceedings of the 5th International Workshop on Bioinformatics; August 21-4, 2005. Chicago, Illinois. New York: ACM Press; 2005. pp. 21-28.
26. Wei Z, Wang K, Qu HQ, Zhang H, Bradfield J, Kim C, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet 2009; 5:e1000678.
27. Roshan U, Chikkagoudar S, Wei Z, Wang K, Hakonarson H. Ranking causal variants and associated regions in genome-wide association studies by the support vector machine and random forest. Nucleic Acids Res 2011; 39:e62.
28. Prasad TS, Kandasamy K, Pandey A. Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol 2009; 577:67-79.
29. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92:414-41 7.
30. Segre AV, Groop L, Mootha VK, Daly MJ, Altshuler D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 2010; 6:8.
31. Vastrik I, D'Eustachio P, Schmidt E, Gopinath G, Croft D, de Bono B, et al. Reactome: a knowledge base of biologic pathways and processes. Genome Biol 2007; 8:R39.1-R39.13.
32. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003; 13:2129-2141.
33. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 437:1032-1037.
34. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999; 27:29-34.
35. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5:e1000529.
36. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda) 2011; 1:457-470.
37. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet 2012; 8:e1002639.
38. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010; 26:2474-2476.
39. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013; 45:1238-1243.
40. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010; 38 (Web Server issue):W214-W220.
41. Cross DS, Ivacic LC, Stefanski EL, McCarty CA. Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project. BMC Genet 2010; 11:51.
42. Xu WH, Long JR, Zheng W, Ruan ZX, Cai Q, Cheng JR, et al. Association of thymidylate synthase gene with endometrial cancer risk in a Chinese population. Cancer Epidemiol Biomarkers Prev 2009; 18:579-584.
43. Emery P, Buch MH. Towards an optimum strategy in rheumatoid arthritis. Lancet 2012; 379:1682-1684.
44. Oguro R, Kamide K, Katsuya T, Akasaka H, Sugimoto K, Congrains A, et al. A single nucleotide polymorphism of the adenosine deaminase, RNA-specific gene is associated with the serum triglyceride level, abdominal circumference, and serum adiponectin concentration. Exp Gerontol 2012; 47:183-187.
45. Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J 2014; 14:35-40.
46. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004; 13:1303-1313.
47. Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol 2010; 6:249-259.
48. Gjorlund MD, Nielsen J, Pankratova S, Li S, Korshunova I, Bock E, et al. Neuroligin-1 induces neurite outgrowth through interaction with neurexin-1beta and activation of fibroblast growth factor receptor-1. FASEB J 2012; 26:4174-4186.
49. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3:912-920.
50. Dolnick BJ, Angelino NJ, Dolnick R, Sufrin JR. A novel function for the rTS gene. Cancer Biol Ther 2003; 2:364-369.
51. Dolnick BJ. The rTS signaling pathway as a target for drug development. Clin Colorectal Cancer 2005; 5:57-60.
52. Inoue M, Robien K, Wang R, Van Den Berg DJ, Koh WP, Yu MC. Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study. Carcinogenesis 2008; 29:1967-1972.
53. Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004; 5:559-569.